OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J. Motzer, Paul Russo, Viktor Grünwald, et al.
The Lancet (2023) Vol. 401, Iss. 10379, pp. 821-832
Closed Access | Times Cited: 116
Robert J. Motzer, Paul Russo, Viktor Grünwald, et al.
The Lancet (2023) Vol. 401, Iss. 10379, pp. 821-832
Closed Access | Times Cited: 116
Showing 1-25 of 116 citing articles:
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 15, pp. 1359-1371
Closed Access | Times Cited: 96
Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 15, pp. 1359-1371
Closed Access | Times Cited: 96
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles, Laurence Albigès, Axel Bex, et al.
Annals of Oncology (2024) Vol. 35, Iss. 8, pp. 692-706
Closed Access | Times Cited: 51
T. Powles, Laurence Albigès, Axel Bex, et al.
Annals of Oncology (2024) Vol. 35, Iss. 8, pp. 692-706
Closed Access | Times Cited: 51
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Mohamad E. Allaf, Se-Eun Kim, Viraj A. Master, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. 1038-1052
Closed Access | Times Cited: 28
Mohamad E. Allaf, Se-Eun Kim, Viraj A. Master, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. 1038-1052
Closed Access | Times Cited: 28
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
David A. Braun, Giorgia Moranzoni, Vipheaviny Chea, et al.
Nature (2025)
Open Access | Times Cited: 4
David A. Braun, Giorgia Moranzoni, Vipheaviny Chea, et al.
Nature (2025)
Open Access | Times Cited: 4
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma
Jens Bedke, Yasmin Abu Ghanem, Laurence Albigès, et al.
European Urology (2025)
Closed Access | Times Cited: 2
Jens Bedke, Yasmin Abu Ghanem, Laurence Albigès, et al.
European Urology (2025)
Closed Access | Times Cited: 2
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Christopher W. Ryan, Catherine M. Tangen, Elisabeth I. Heath, et al.
The Lancet (2023) Vol. 402, Iss. 10407, pp. 1043-1051
Open Access | Times Cited: 32
Christopher W. Ryan, Catherine M. Tangen, Elisabeth I. Heath, et al.
The Lancet (2023) Vol. 402, Iss. 10407, pp. 1043-1051
Open Access | Times Cited: 32
Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma
Charles B. Nguyen, Eugene Oh, Piroz Bahar, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 601-601
Open Access | Times Cited: 10
Charles B. Nguyen, Eugene Oh, Piroz Bahar, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 601-601
Open Access | Times Cited: 10
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study
Talal El Zarif, Karl Semaan, Wanling Xie, et al.
European Urology (2024) Vol. 86, Iss. 6, pp. 503-512
Closed Access | Times Cited: 9
Talal El Zarif, Karl Semaan, Wanling Xie, et al.
European Urology (2024) Vol. 86, Iss. 6, pp. 503-512
Closed Access | Times Cited: 9
Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Ting Yan, Yu Lun, Jiwen Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Ting Yan, Yu Lun, Jiwen Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
UroPredict: Machine learning model on real-world data for prediction of kidney cancer recurrence (UroCCR-120)
G. Margue, Loïc Ferrer, Guillaume Etchepare, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 8
G. Margue, Loïc Ferrer, Guillaume Etchepare, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 8
Biomarkers and treatment updates in renal cell carcinoma
Jasmin Alia Terzic
memo - Magazine of European Medical Oncology (2025)
Closed Access | Times Cited: 1
Jasmin Alia Terzic
memo - Magazine of European Medical Oncology (2025)
Closed Access | Times Cited: 1
Advances in Adjuvant Therapy for Renal Cell Carcinoma: Perspectives on Risk Stratification and Treatment Outcomes
Junya Furukawa, Ryotaro Tomida, Kei Daizumoto, et al.
International Journal of Urology (2025)
Open Access | Times Cited: 1
Junya Furukawa, Ryotaro Tomida, Kei Daizumoto, et al.
International Journal of Urology (2025)
Open Access | Times Cited: 1
Oncology: What You May Have Missed in 2024
Zainab Ali Amer Al Maqrashi, Sze Wah Samuel Chan, Zeba Siddiqui, et al.
Annals of Internal Medicine (2025)
Closed Access | Times Cited: 1
Zainab Ali Amer Al Maqrashi, Sze Wah Samuel Chan, Zeba Siddiqui, et al.
Annals of Internal Medicine (2025)
Closed Access | Times Cited: 1
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N. Lara, Catherine M. Tangen, Elisabeth I. Heath, et al.
European Urology (2024) Vol. 86, Iss. 3, pp. 258-264
Closed Access | Times Cited: 7
Primo N. Lara, Catherine M. Tangen, Elisabeth I. Heath, et al.
European Urology (2024) Vol. 86, Iss. 3, pp. 258-264
Closed Access | Times Cited: 7
Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
Karen Abboud, Godsfavour Umoru, Abdullah Esmail, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1433-1433
Open Access | Times Cited: 13
Karen Abboud, Godsfavour Umoru, Abdullah Esmail, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1433-1433
Open Access | Times Cited: 13
Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma
Richard Culliford, Samuel Lawrence, C. Mills, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Richard Culliford, Samuel Lawrence, C. Mills, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
Robert J. Motzer, Axel Bex, Paul Russo, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 5
Robert J. Motzer, Axel Bex, Paul Russo, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 5
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis
Clara Cerrato, Fabio Crocerossa, Michele Marchioni, et al.
European Urology Oncology (2024) Vol. 7, Iss. 5, pp. 1005-1014
Closed Access | Times Cited: 4
Clara Cerrato, Fabio Crocerossa, Michele Marchioni, et al.
European Urology Oncology (2024) Vol. 7, Iss. 5, pp. 1005-1014
Closed Access | Times Cited: 4
A Review of Neoadjuvant Therapy for Localized and Locally Advanced Renal Cell Carcinoma
Qian Qin, Isamu Tachibana, Vitaly Margulis, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 312-312
Open Access
Qian Qin, Isamu Tachibana, Vitaly Margulis, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 312-312
Open Access
Adjuvant Therapy in Renal Cell Carcinoma
Patrick L. Sweeney, Kelly N. Fitzgerald
Advances in Oncology (2025)
Closed Access
Patrick L. Sweeney, Kelly N. Fitzgerald
Advances in Oncology (2025)
Closed Access
B2B: Kidney Cancer Summary
Simon Tanguay, Maxine Tran, Vedang Murthy, et al.
Société Internationale d’Urologie Journal (2025) Vol. 6, Iss. 1, pp. 15-15
Open Access
Simon Tanguay, Maxine Tran, Vedang Murthy, et al.
Société Internationale d’Urologie Journal (2025) Vol. 6, Iss. 1, pp. 15-15
Open Access
Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?
Andreea Paroşanu, Cornelia Nititpir, Ioana-Miruna Stanciu, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 543-543
Open Access
Andreea Paroşanu, Cornelia Nititpir, Ioana-Miruna Stanciu, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 543-543
Open Access
Recent Developments in the Management of Renal Cell Cancer
Yu‐Wei Chen, Justine Panian, Brent S. Rose, et al.
JCO Oncology Practice (2025)
Closed Access
Yu‐Wei Chen, Justine Panian, Brent S. Rose, et al.
JCO Oncology Practice (2025)
Closed Access
Adjuvant personalized cancer vaccine: is this the end of metastatic kidney cancer
Manuela Schmidinger, Irene Huebner-Resch
Nature Reviews Urology (2025)
Closed Access
Manuela Schmidinger, Irene Huebner-Resch
Nature Reviews Urology (2025)
Closed Access
